Loading...
XASX
MAP
Market cap14mUSD
Jul 10, Last price  
0.04AUD
1D
2.50%
1Q
-42.25%
IPO
-89.07%
Name

Microba Life Sciences Ltd

Chart & Performance

D1W1MN
XASX:MAP chart
P/E
P/S
1.34
EPS
Div Yield, %
Shrs. gr., 5y
9.05%
Rev. gr., 5y
40.04%
Revenues
16m
+29.60%
1,828,1552,909,0263,732,4434,688,6455,420,13612,090,05515,669,089
Net income
-15m
L-25.07%
-4,733,829-6,650,667-7,523,752-11,470,429-12,680,212-19,938,485-14,939,471
CFO
-12m
L-22.83%
-3,620,558-4,323,278-7,181,584-10,448,812-12,393,828-15,566,936-12,012,511

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Microba Life Sciences Limited, established in Brisbane, Australia, in 2017, specializes in providing sophisticated microbiome testing and analytical services. These offerings reach clinicians, individual consumers, and research customers across key international markets, including Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. The company delivers pathology, therapeutic, and diagnostic solutions deeply rooted in human gut microbiome science. Central to its operations is a comprehensive Databank, invaluable for unearthing therapeutic leads, fostering consumer health advancements, and identifying crucial diagnostic biomarkers. Moreover, Microba leverages a data-driven therapeutics platform to engineer innovative monoclonal microbial cell therapies aimed at treating inflammatory bowel disease, enhancing cancer immunotherapy, and managing autoimmune disorders.
IPO date
Apr 05, 2022
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT